Clinical Trial Update: Maintenance Therapy of Hypomethylating Agent (HMA) in Favorable Risk Acute Myeloid Leukemia (AML) Patients [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating maintenance therapy with a hypomethylating agent in favorable-risk acute myeloid leukemia patients is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Hypomethylating agent

Snippet

Sponsor: The First Affiliated Hospital of Soochow University | Conditions: Acute Myeloid Leukemia | Phase 2 | Status: RECRUITING